SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in three upcoming investor conferences in August.
LifeSci Partners Private Company Virtual Summer Symposium
Date: Tuesday, August 4, 2020
Time: 3:30 p.m. ET / 12:30 p.m. PT
Piper Sandler Summer 2020 Private Company Showcase
Date: Monday, August 10, 2020
Time: 4:00 p.m. ET / 1:00 p.m. PT
BTIG Virtual Biotechnology Conference
Analyst-Led Fireside Chat
Date: Tuesday, August 11, 2020
Time: 12:30 p.m. ET / 9:30 a.m. PT
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.